Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
K. Chichirelo-Konstantynovych (Vinnytsya, Ukraine), L. Moroz (Vinnytsya, Ukraine), T. Konstantynovych (Vinnytsya, Ukraine). Immunity status of community acquired pneumonia (CAP) young patients according concomitant cytomegalovirus persistence (CMVP). 2376

Member's Comments

No comment yet.

Related content which might interest you: Community-acquired pneumonia (CAP) with cytomegaloviral (CMV) persistence at young adults: prevalence and reciprocal burdening Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Prevalence of hyponatremia (HN) in children with community acquired pneumonia (CAP) and its relation to disease severity, outcomes Source: Virtual Congress 2021 – Acute paediatric respiratory infections Year: 2021 Determinants of vaccination in patients with community acquired pneumonia (CAP) or chronic lung diseases Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004 I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP) Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 The severity of Pneumocystis pneumonia without human immunodeficiency virus infection (non-HIV PCP) might be underestimated by conventional diagnostic rules for community-acquired pneumonia (CAP) Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Determination of community acquired pneumonia (CAP) severity in pregnant (pr.) Source: Virtual Congress 2021 – Clinical features and challenges of COVID-19 Year: 2021 Factors related to obtain an etiological diagnosis in community acquired pneumonia (CAP) Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Biomarkers to discriminate bacterial, viral and mixed community acquired pneumonia (CAP) Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 The predictive role of TLR4 +3725 G/C polymorphism in community-acquired pneumonia (CAP) severity course among young respondents with cytomegaloviral persistence (CMVP) Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 Role of viruses, alone and in association with bacteria, in adults hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Aetiology, diagnosis and outcomes in community-acquired pneumonia Year: 2011 Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Clinical stability in patients with community- acquired pneumonia (CAP) Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011 Cardiac diseases in patients with community acquired pneumonia (CAP) Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 Detection of liver function in patients with severe community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged >=75 yrs Source: Eur Respir J 2001; 17: 200-205 Year: 2001 Biological markers in hospitalised patients with community acquired pneumonia (CAP) Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010